Access & reimbursement

Merck KGaA’s Saturnus Bio bet signals a shift to genotype-driven cardiology, and a looming readiness gap for health systems

Same country, different risks: why Iranian women’s heart disease profiles expose a blind spot in prevention policy

Migraine Prevention Gets a Wider Door

Indigenous cardiovascular inequity is not a data gap. It is a policy failure

Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate

MS Regulators Are No Longer Reading the Same Risk

NTDs Are Now A Human-Rights Issue. Budgets Must Follow.

Cardiology has too many dashboards. The danger is forgetting the patient

GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
